AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes
- Details
- Category: AstraZeneca
AstraZeneca and Oracle Health and Life Sciences announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner. Abbott launches 'Mind Your Behind' campaign to encourage Americans 45+ to screen for colorectal cancer
- Details
- Category: Abbott
Abbott, the global healthcare leader, launched “Mind Your Behind,” a new Cologuard Plus® awareness campaign featuring baseball legend and three-time MVP Albert “The Machine” Pujols and catcher for the Seattle Mariners Cal “The Big Dumper” Raleigh to encourage adults to prioritize colorectal cancer screening. Pfizer advances today's cancer care and tomorrow's potential breakthroughs at ESMO
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer. An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
- Details
- Category: Business
We are proud Europeans. We serve as Chairs of companies born from European science, rooted in laboratories across Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, the UK, and beyond. Our duty is to safeguard our companies’ future so that we can continue to discover and develop life-changing medicines for patients.
The pharmaceutical sector is one of our continent's great post-war achievements. Built on investment in science, world-class universities, and the determination to discover medicines that change lives.
Sanofi and Cheplapharm to create new strategic partnership in mature medicines
- Details
- Category: Sanofi
Sanofi and Cheplapharm, a European leader in well-established medicines, announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014. AstraZeneca expands company’s $100m+ commitment to advance youth health equity in more than 60 countries
- Details
- Category: AstraZeneca
AstraZeneca announced a new five-year phase of its flagship Young Health Programme (YHP) in partnership with UNICEF and 60 non-governmental organisations (NGOs), extending its investment in youth health equity to over $100m since the YHP’s inception in 2010.
The programme, which supports young people in underserved communities, is committed to preventing conditions such as cancer, diabetes, heart disease and lung disease by educating and activating young people to
Pfizer and Valneva's Lyme disease vaccine candidate Marketing Authorization Application validated by European Medicines Agency
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.
The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524), which investigated whether the vaccine candidate, PF-07307405, prevented Lyme disease cases in individuals aged five years and older.
More Pharma News ...
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- Sanofi Foundation opens new chapter centered on future generations
- Bristol Myers Squibb evolves and expands Standing in the Gaap to advance more equitable care in multiple myeloma
- Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
- Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
- Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'
- Pfizer's Phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis